tirzepatide trial Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice SURPASS-CVOT Published: Large Trial Confirms

Adding a protein source to every mealeven if portions are small due to appetite suppressionpreserves muscle mass and reduces soreness

Sip throughout the day between meals rather than chugging large amounts at once

Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy

These results are drawn from peer-reviewed publications in the New England Journal of Medicine and The Lancet

In November 2023, the FDA granted approval for tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity

For va glp-1 coverage, the first practical step is to explain that formulary and employer-plan rules can vary inside the same insurer